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status of Cardiac Transplantation with a Report ofthe First Year's
Experience at Henry Ford Hospital
Fraser M. Keith, MD,* Donald J. Magilligan, Jr, MD,* Jeffrey B. Lakier, MD,* and
Conrad Drost, RN*

Cardiac transplantation is now widely accepted as effective treatment for selected patients with endstage heart disease. Improvements in immunosuppressive treatment and monitoring in the past 15
years have resulted in impressive one-year and five-year sur\'ival rates of 80% and 60%. In general,
survivors have enjoyed a considerably improved quality of life. A cardiac transplantation program
was initiated at Henry Ford Hospital in 1985, and a total of 15 patients received heart transplants in
thefirst 12 months. Fourteen patients are currently alive and well at various stages posttransplant.
This early clinical success has prompted the consideration of both combined heart-lung
tramplantation and mechanical left ventricular support at Henrv Ford Hospital in the future. (Henry
FordHosp MedJ 1986:34:197-201)

A

fter nearly a decade, cardiac transplantation reemerged in
the late 1970s as effective treatment for selected patients
with end-stage cardiac disease. Since then a rapid increase in
both the number of recipients and transplant centers has occuned. An intemational registry for heart and heart-lung transplant recipients was established in 1984 (I), The number of patients in the registry currendy exceeds 2,800; over 700 were
accounted for in 1985 alone. Some authorities predict that as
many as 2,000 cardiac transplants per year could be performed
in the United States using cunent recipient and donor selection
criteria (2,3).
The major stimulus for renewed interest in cardiac transplantation is the increased survival and freedom from morbidity afforded by cyclosporine immunosuppression. Expected survival
rates for cardiac transplant recipients in 1986 are 80% and 60%
at one and five years, respectively. The quality of life is cleariy
improved following cardiac transplantation, and many recipients resume full-time employment.
The cardiac transplantation program at Henry Ford Hospital
was initiated in 1985. This was a cooperative multilevel and
multidisciplinary venture throughout the hospital. After three
months of laboratory experiments, the first human cardiac transplant at Henry Ford Hospital was perfonned in April 1985. A
total of 15 patients received transplants during the first 12 months
ofthe program. To date, 14 of these 15 patients are alive and well
at various stages of posttransplant; the one death was attributed
to disseminated aspergillosis. This presentation oudines some
ofthe important issues in human cardiac transplantation and discusses the results of the recent Henry Ford Hospital experience.

Recipient Selection
Careful recipient selection is one of the most important determinants of success in a cardiac transplant program. Medical,
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psychosocial, and financial issues must be considered. At
Henry Ford Hospital a pretransplant evaluation is performed by
a committee which consists of the medical-surgical group, a social worker, psychiatrist, and chaplain. Full support of the transplant committee must be obtained before an individual is added
to the list of patients awaiting transplantation. Additional input
is obtained from specialists in infectious diseases, immunopathology, pathology, hypertension/nephrology, nursing, and
rehabilitation.
Cardiac transplantation is considered for patients with endstage cardiac disease only when other, more conventional treatment has failed or is contraindicated. As a group, these patients
have an extremely poor prognosis. Data from Stanford University show a mean survival rate of six weeks for patients who have
been accepted for transplantation but for whom no suitable donor can be found (4). Despite this survival advantage, the main
reason for cardiac transplantation at Henry Ford Hospital is the
symptomatic relief of severe congestive heart failure.
The primary diagnoses of the 15 patients who received transplants at Henry Ford Hospital in 1985 are listed in Table I . NaTable 1
Primary Diagnosis
Idiopathic cardiomyopathy
Ischemic cardiomyopathy
Valvular heart disease
Olher

4 patients
8 patients
2 patients
I patient
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Table 3
Recipient Demographics

Table 2
Criteria for Recipient Selection: Optimal Conditions
Age less than 55 years
Terminal cardiac disease despite optimal conventional medicaysurgical therapy
Life expectancy less than one year
Noncardiac function normal or reversibly impaired
Pulmonary vascular resistance less than 2 Wood units
No active infection, cancer, or other systemic illness
Good psychosocial profile
Good record of medical compliance
Adequate finances
Well-informed and motivated

Age
Sex (No.)
Race (No.)

45 years (mean)
Males (13)
Caucasian (12)

29 to 58 years (range)
Females (2)
Black (3)

generally only younger donors are chosen. Nevertheless, a
growing donor shortage and increasingly ill recipients have
forced some groups to extend the donor age criteria. In most
cases, a careful review of the donor's history, physical examination, electrocardiogram, and echocardiogram is sufficient to detionally, ischemic cardiomyopathy is probably the most frequent
tect significant cardiac abnormalities. Cardiac catheterization
indication for cardiac transplantation, and more patients are
and coronary angiography are rarely indicated. Though it is not
being refened after unsuccessful myocardial revascularization
critical, an attempt is made to match the size of donor and recipwith or without concomitant valve or aneurysm procedures.
ient. Long-standing cardiac failure and pulmonary hypertension
Moribund patients with an intraaortic balloon pump and receivresult in global cardiomegaly and frequent enlargement of the
ing inotropic support or other mechanical support are also a
great vessels. In these circumstances it is technically easier to
growing fraction of the cardiac transplant population. Overall,
graft a heart from a larger donor. Similar allowances are also
clinical judgment is probably as important in determining the
made for recipients with high pulmonary vascular resistance.
optimal timing for transplantation as are the objective measures
of cardiac failure, such as cardiac index, ejection fraction, and
The donor's and recipient's ABO systems must be compatiend-diastolic pressure. The optimal recipient criteria based on
ble, but matching the minor blood group antigens is unnecescunent opinion are outlined in Table 2 (5).
sary. HLA matching is probably beneficial for cardiac recipThe age criteria for transplantation have been challenged by
ients, but time constraints and the limited donor pool prevent
many groups. Patients older than 55 years have had transplants
routine use. Prospective HLA antibody screening is performed
and, if otherwise carefully selected, do as well as their younger
for all potential cardiac recipients. Fortunately, cytotoxic anticounterparts. Undoubtedly, the upper age limit at an institution
bodies against HLA antigens are much less common in cardiac
is partly determined by the number of available donors and the
than in renal transplant candidates. Results of the fonnal donornumber of young recipients already on the waiting list. The derecipient cross-match are unnecessary preoperatively unless
mographics of the cardiac transplant recipients at Henry Ford
screening indicates recipient positivity against 15% or more ofa
Hospital are provided in Table 3.
panel of random donor lymphocytes. We have yet to encounter a
patient with this degree of positivity. Donors are also screened
Elevation ofthe pulmonary vascular resistance detected at the
for the presence of potentially transmissible diseases such as
time of right heart catheterization is a significant concern for
AIDS, hepatitis-B, and nonprimary central nervous system canpatients with long-standing congestive heart failure. The orthocer A significant history of recent dmg abuse, particularly intratopically transplanted heart is poorly prepared to funcrion
venous dmgs, precludes cardiac donation.
acutely with a high afterload on the right ventricle. Fortunately,
patients rarely have fixed elevations of pulmonary vascular reThe mechanism of brain death has not been shown to influsistance even in the setting of long-standing heart disease. At
ence the results of organ transplantation. In our experience at
Henry Ford Hospital an attempt is made to normalize pulmonary
Henry Ford Hospital, the two major causes of brain death have
resistance during catheterization by administration of oxygen
been traumatic brain injury and cerebral hemorrhage from
and systemic vasodilators. Alternately, these patients might be
vascular abnormalities. Brain death sets in motion a complex
considered for combined heart and lung transplantation or hetchain of physiologic events which uldmately result in cardioerotopic heart transplantation.
vascular collapse and arrest of the circulatory system. The
potential organ donor requires careful monitoring to mainThe goal of cardiac transplantation is successful rehabilitation
tain homeostasis. Fluid balance and electrolyte management are
ofthe patient with a return toward a normal level of activity.
complicated by the presence of diabetes insipidus. Temperature
Since life expectancy after cardiac transplantation is unlikely to
regulation is disturbed with the appearance of either hypertherbe normal when compared with age-matched controls, the transmia or hypothermia. Sepsis from pneumonia, urinary tract
plant recipient should be highly motivated and have a realisinfections, or traumatic or surgical wounds must be treated agtic attitude and definite ambition. Stress is always present, and
gressively with appropriate antibiotics. Initially, hypotension
good emotional and family support is essential. Alcoholism and
resulting from fluid restriction, diabetes insipidus, or diuretic
dmg abuse are contraindications for transplantation. The best
therapy can be reversed by fluid administration. Judicious use of
recipients are mature, intelligent individuals with a good record
dopamine and colloid are also beneficial in maintaining carof medical compliance and a short history of disability.
diovascular stability. The dosage limits or duration of dopamine administration have not been cleariy established. However,
Donor Selection
most cardiac groups find that doses of over 5 (jig/kg/min are
Cunent optimal donor criteria are presented in Table 4 (6,7).
excessive.
Coronary artery disease is so prevalent in North America that
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Table 4
Criteria for Donor Selection: Optimal Conditions
Age: Males less than 35 years of age, females less than 40 years of age.
Size: Within 20% body weight of the recipient.
ABO blood group compatible.
Hemodynamically stable: Dopamine less than 5 p-g/kg/min.
Absence of significant cardiac history or injury.
Absence of transmissible diseases: hepatitis, AIDS, cancer, etc.

Table 5
Biopsy Interpretation
Grade

Histology

No rejection
Mild rejection

No infiltrate
Mononuclear infiltrate
Perivascular to interstitial location
No myocyte necrosis present
Mononuclear interstitial infiltrate
Mild to moderate myocyte necrosis
Marked myocyte necrosis
Infiltrate with polymorphonuclear leukocytes or
hemorthage

Moderate rejection
Severe rejection

Not enough thanks can be given to the families of the donors
who make these unselfish gifts at a time of great personal grief.
Increasing public awareness of the success of transplantation
combined with progressive policy decisions on the part of govemment at multiple levels have helped increase the number of
organ donors. We expect that required-request legislation will
have a further positive effect. Each hospital must fonnulate its
own definitions of brain death, although nationally recognized
guidelines are available (8,9). Contact with a number of excellent regional organ procurement networks ensures optimal utilization of the organs to be donated once brain death has been
established.

Cardiac IVansplantation: The Operation
The surgical procedure for orthotopic cardiac transplantation
was originally described by Lower and Shumway (10) and later
modified by Barnard (II), Initially, simultaneous donor and recipient operations were performed in adjacent operating rooms
to minimize the period of cardiac graft ischemia, Cunent hypothermic cardioplegic techniques ensure good myocardial
preservation for periods of up to four hours in humans and considerably longer in animals. This has increased the donor pool
by allowing donor organ procurement up to 1,000 miles from the
site of implantation (12,13). Close coordination between donor
and recipient teams is required to minimize graft ischemic
times, particulariy at these long distances. Fortunately, our
transplant program has been able to secure all donors from
within a 250 mile radius. Mean ischemic time was 107 minutes
with a range of 53 to 184 minutes.
Cardiac recipients present challenging problems to the anesthetist. The induction and prebypass phases require careful
monitoring andtitrationof anesthesia to maintain hemodynamic
stability. Recipients at Henry Ford Hospital have their blood
ultrafiltered during cardiopulmonary bypass. Our clinical
impression is that this reduction in total body water improves
pulmonary function and facilitates early extubation postoperatively. The most frequent intraoperative problem in this
group of patients is bleeding. Major risk factors that cause
bleeding are reoperation, preoperative anticoagulant therapy,
and congestive hepatic dysfunction.
All grafts have functioned sufficiently after implantation to
allow weaning from cardiopulmonary bypass. Patients routinely
receive small doses of inotropes postoperatively. Early in our experience at Henry Ford Hospital, we learned thatright-sidedhemodynamics were equally if not more important than left-sided
hemodynamics after cardiac transplantation. Consequently, a
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pulmonary artery thermodilution cardiac output catheter is now
inserted routinely before separation from cardiopulmonary bypass. Reduction of right ventricular afterload with nitroglycerin
or prostaglandins has been helpful in some patients.

Immune Suppression
Early in the cardiac transplant experience the two major
sources of morbidity and mortality were rejection and infection.
The 12-month survival rate in 1968 was 20%, with almost all of
the deaths occurring from rejection and infection within the first
three months after transplantation. Clearly, the antirejecdon
protocols available then had too nanow a margin between over
and under immune suppression.
In the 1970s cardiac transplantation fell into disfavor, and only
a few groups continued this procedure. Two notable achievements were made at Stanford University during this period: introduction of endomyocardial biopsy as a routine clinical tool in
the evaluation of rejection (14), and development of antihuman
thymocyte sera for prophylaxis and treatment of rejecdon (15).
By the mid-1970s, the 12-month transplantation survival rate at
Stanford improved to 60%, and other American, European, and
South African centers began to report similar results. Endomyocardial biopsy is the "gold standard" against which all
other diagnostic techniques for rejection must be compared. It is
a simple and relatively safe procedure that can be repeated as
often as necessary. The histologic classification of cardiac rejection has been well described (16) and is presented in Table 5.
Although the threat is always present, the incidence of rejection declines markedly after the first three months (17). Presently, almost all patients have at least one histologically diagnosed acute rejection episode in the first three months posttransplant. Antirejection surveillance, therefore, is most intense
during this period, and endomyocardial biopsies are repeated
every one or two weeks. Beyond the three-month period, the interval between successive biopsies is gradually extended; currently, one-year survivors at Henry Ford Hospital are biopsied
every three months.
Another major advance in the history of cardiac transplantation was the discovery of cyclosporine, a naturally occuning
peptide isolated from two species of soil fungi. This remarkable
dmg has potent and specific effects on cell-mediated immunity.
Initially, cyclosporine was used as the sole immunosuppressive
dmg, but clinical experience has shown it to be most effective
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Table 6
Immune Suppression: Regimen for Cardiac
Transplant Recipients
Steroids

ALG

Cyclo.sporine

Azathioprine

Methylprednisolone intravenously.
500 mg intraoperatively.
IOO mg every 8 hours for 24 hours.
50 mg every 8 hours for 24 hours.
Prednisone orally 1 mg/kg/day tapered to
0.2 mg/kg/day by 4 to 6 weeks.
10 to 15 mg/kg/day intravenously to reduce total
peripheral blood lymphocytes less than 200.
Stop when serum cyclosporine level greater than
100 ng/mL.
6 to 8 mg/kg/day orally. Start when taking fluids
orally and renal function adequate.
Adjust every 12-hour dose to obtain targeted
trough serum level.
I to 2 mg/kg/day orally. Start when taking fluids
orally and maintain total leukocytes greater
than 5,000 and platelets greater than 100,000
in peripheral blood.

when combined with either prednisone or azathioprine. The immunosuppressive protocol in use at Henry Ford Hospital is presented in Table 6.
Cyclosporine therapy has been responsible for the latest 15%
to 20% across-the-board improvement in survival rates following cardiac transplantation. It has nanowed the success rate differences between experienced centers and those just starting
transplant programs. This has encouraged rapid proliferation of
transplant centers worldwide.
When cyclosporine therapy is compared with "conventional" immunosuppressive regimens (those used in the precyclosporine era), mortality from rejection and infection is dramatically reduced (17). The incidence of acute rejection is
probably unchanged, but the rejection process is slowed and
more amenable to reversal. Preservation of humoral and nonspecific immunity also results in fewer deaths from infection,
ahhough the overall incidence of infection probably remains
unchanged.
Complications of long-term immunosuppressive therapy include an increased risk of opportunistic infections and cancer
(18). The development of accelerated atherosclerosis within the
graft is one complication specific to cardiac transplantation and
is a leading cause of late death. Routine, annual coronary angiography is performed to detect this complication, and significant coronary lesions are an indication for retransplantation.
Cyclosporine has its own special long-term problems, notably
nephrotoxicity and the almost universal incidence of hypertension among cardiac transplant recipients. Acute cyclosporine
nephrotoxicity is frequendy observed posttransplant in patients
with preoperative renal dysfunction (19). This complication is
usually manifested as acute oliguric renal dysfunction in the immediate posttransplant period. For this reason, we avoid the
perioperative use of cyclosporine and rely on antilymphoblast
globulin for immune suppression during the first two to three
days. Cyclosporine is administered when cardiorespiratory,
gastrointestinal, and renal function have stabilized. Cyclosporine levels are monitored daily, and the dose is adjusted frequently to ensure optimal efficacy and minimum toxicity. When
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more insidious chronic nephrotoxicity of cyclosporine occurs
after several months of therapy, serial monitoring of renal function reveals slow deterioration. This has been the subject of
much recent concern and research. Cyclosporine analogs, multidrug protocols, and determination of optimum long-term
cyclosporine levels should diminish this problem in the future.

Future Directions
The major breakthrough for solid organ transplantation will
come with the development of methods for inducing specific
tolerance. This will obviate the need for long-term immunosuppressive therapy and eliminate the associated problems of infection, cancer, and adverse dmg reactions. Much experimental
progress should affect clinical practice soon.
New analogs of cyclosporine which are undergoing clinical
trials may or may not have advantages over the parent compound. Monoclonal antibodies against specific classes of human
T-cells are now available for clinical use and are effective in
treatment of resistant-rejection episodes. Their ultimate role,
however, remains to be defined. Other forms of immune modification by pretransplant blood transfusion or total lymphoid inadiation are beneficial for renal transplantation but are not yet
widely practiced in cardiac transplantation.
Short-term mechanical support or replacement ofthe heart is
viewed as a bridge to cardiac transplantation. These devices are
effective in salvaging patients until suitable donors can be
found, but the demand for cardiac donors already exceeds the
supply. Thus, the "bridge" concept does not solve the problem;
it merely increases the number of seriously ill patients awaiting
transplantation. Xenografts and a new generation of totally implantable mechanical devices are potential sources for cardiac
replacement in the future.
The first year's experience in cardiac transplantation at Henry
Ford Hospital has been exceptionally gratifying for everyone involved. Future directions for the program include the initiation
of combined heart-lung transplantation and temporary left ventricular support with a mechanical device. We expect the next 12
months to be equally exciting.

Addendum
Twenty-five patients have undergone orthotopic cardiac transplantation at Henry Ford Hospital as of August 1986. Five patients have been followed in excess of one year, and all survivors
are cunently well.
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